- ISIN
- US60770K1079
- CUSIP
- 60770K107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 7, 2018
Highlights
- Market Cap
- $23.44B
- Enterprise Value
- $22.78B
- EPS (TTM)
- -$8.16
- Total Revenue (TTM)
- $2.23B
- Gross Profit (TTM)
- -$309.00M
- EBITDA (TTM)
- -$3.02B
- Year Range
- $22.28 - $67.74
- Target Price
- $36.00
- ROA (TTM)
- -27.80%
- ROE (TTM)
- -43.12%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MRNA Performance Chart
Moderna, Inc. (MRNA) is up 101.2% since the beginning of the year. At $59 per share, MRNA is trading 12.4% below its 52-week high of $68. Investors who bought $1,000 worth of MRNA shares 5 years ago would now be looking at an investment worth $280.
Loading charts...
Returns By Period
Moderna, Inc. (MRNA) has returned 101.24% so far this year and 129.13% over the past 12 months.
Moderna, Inc.
- 1D
- -7.22%
- 1M
- 26.59%
- YTD
- 101.24%
- 6M
- 70.04%
- 1Y
- 129.13%
- 3Y*
- -20.59%
- 5Y*
- -22.48%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
MRNA Monthly Returns History
Based on dividend-adjusted daily data since Dec 7, 2018, MRNA's average daily return is +0.15%, while the average monthly return is +3.47%. At this rate, an investment would double in approximately 1.7 years.
Historically, 53% of months were positive and 47% were negative. The best month was Nov 2020 with a return of +126.4%, while the worst month was Aug 2024 at -35.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.
On a daily basis, MRNA closed higher 48% of trading days. The best single day was Feb 25, 2020 with a return of +27.8%, while the worst single day was Aug 1, 2024 at -21.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 49.44% | 21.56% | -5.17% | -9.57% | 2.72% | 25.76% | 101.24% | ||||||
| 2025 | -5.19% | -21.46% | -8.43% | 0.67% | -6.94% | 3.88% | 7.14% | -18.50% | 7.22% | 5.15% | -4.34% | 13.51% | -29.08% |
| 2024 | 1.61% | -8.72% | 15.52% | 3.52% | 29.23% | -16.70% | 0.40% | -35.08% | -13.66% | -18.66% | -20.79% | -3.44% | -58.19% |
| 2023 | -1.98% | -21.16% | 10.64% | -13.47% | -3.90% | -4.86% | -3.16% | -3.90% | -8.65% | -26.46% | 2.29% | 27.99% | -44.63% |
| 2022 | -33.33% | -9.29% | 12.15% | -21.97% | 8.12% | -1.71% | 14.87% | -19.39% | -10.60% | 27.13% | 17.02% | 2.11% | -29.28% |
| 2021 | 65.75% | -10.60% | -15.41% | 36.56% | 3.46% | 27.01% | 50.48% | 6.53% | 2.17% | -10.30% | 2.09% | -27.93% | 143.11% |
Benchmark Metrics
Moderna, Inc. has an annualized alpha of 30.75%, beta of 0.78, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 07, 2018.
- This stock participated in 90.47% of S&P 500 Index downside but only 90.16% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 30.75%
- Beta
- 0.78
- R²
- 0.05
- Upside Capture
- 90.16%
- Downside Capture
- 90.47%
Return for Risk
Risk / Return Rank
MRNA ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Moderna, Inc. (MRNA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MRNA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.07 | ||
| Sortino ratioReturn per unit of downside risk | -0.03 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.37 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.66 | 2.78 | +0.87 |
| Martin ratioReturn relative to average drawdown | 7.18 | 12.44 | -5.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Moderna, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Moderna, Inc. was 95.38%, occurring on Nov 20, 2025. The portfolio has not yet recovered.
The current Moderna, Inc. drawdown is 87.75%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -95.38%Nov 2025 | 4y 3mo | — | 4y 10moAug 2021 - now |
2019 bear market2019 | -56.74%Aug 2019 | 3mo 4d | 6mo 25d | 9mo 29dMay 2019 - Feb 2020 |
2020 bear market2020 | -42.71%Sep 2020 | 1mo 20d | 2mo 9d | 3mo 29dJul 2020 - Nov 2020 |
Rate-hike selloffLate 2018 | -38.55%Dec 2018 | 19d | 2mo 2d | 2mo 21dDec 2018 - Feb 2019 |
2020 bear market2020 | -38.50%Dec 2020 | 22d | 29d | 1mo 21dDec 2020 - Jan 2021 |
Drawdown Indicators
| MRNA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.38% | -56.78% | -38.60% |
Max Drawdown (1Y)Largest decline over 1 year | -35.51% | -9.10% | -26.41% |
Max Drawdown (3Y)Largest decline over 3 years | -86.58% | -18.90% | -67.68% |
Max Drawdown (5Y)Largest decline over 5 years | -95.38% | -25.43% | -69.95% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.75% | -1.80% | -85.95% |
Average DrawdownAverage peak-to-trough decline | -57.14% | -10.71% | -46.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.06% | 2.03% | +16.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Moderna, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Moderna, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MRNA relative to other companies in the Biotechnology industry. Currently, MRNA has a P/S ratio of 10.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MRNA in comparison with other companies in the Biotechnology industry. Currently, MRNA has a P/B value of 3.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MRNA
Add Moderna, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MRNA